Can higher doses of @entity11440 improve efficacy in XXXX ?

@entity1 @entity2183 @entity322 @entity1494 @entity191 @entity11440 @entity2182 @entity1566 @entity15
PURPOSE: We evaluated the efficacy and tolerability of higher dose @entity11440 in @entity1 with @entity1494 and @entity15 , @entity1566 or @entity191 . MATERIALS AND METHODS: The study design was a prospective, 12-week dose titration trial of controlled release @entity11440 (OXY-XL). A 7-day washout period was used before initiation of the starting dose of 10 mg OXY-XL. Doses of OXY-XL were increased by 5 mg at weekly intervals to a maximum dose of 30 mg per day guided by @entity1 perception of efficacy versus side effect. Voiding diaries were completed at baseline, and weeks 6 and 12. Post-void residuals were recorded. Criteria for study admission included post-void residual less than 200 ml. RESULTS: Of the 39 @entity1 enrolled in the study 22 had @entity15 , 10 had @entity1566 and 7 had @entity191 . There were 29 @entity1 (74%) and 10 @entity1 (26%). Within 1 week a decrease in the number of voids per day was seen in greater than 50% of the subjects. At the end of the study statistically significant decreases in the number of voids in 24 hours, episodes of @entity2183 and @entity322 episodes were observed. Residual urine remained unchanged from 33.9 +/- 7.6 ml at baseline to 51.3 +/- 10.4 ml after 12 weeks at the final dose (p = 0.17). No @entity1 experienced serious adverse events and none dropped out during the course of the 12-week study. At the end of the study 20.5% of subjects remained on 30 mg, 15.4% on 25 mg, 23.1% on 20 mg, 15.4% on 15 mg and 25.6% on 10 mg OXY-XL. CONCLUSIONS: Aggressive dosing of OXY-XL is safe and effective in @entity1 with @entity1494 . Compared with nonneurogenic @entity2182 , higher doses of OXY-XL (15 mg daily or greater) were requested by 74.4% of the @entity1 in our study. The onset of clinical efficacy can occur within 1 week, and doses up to 30 mg are well tolerated and effective in this population.
